Versant Venture Capital VI, L.P., Ten Percent Owner at Akero Therapeutics, holds 7.20M shares in Monte Rosa Therapeutics (Ticker: GLUE), holds 6.21M shares in Black Diamond Therapeutics (Ticker: BDTX), holds 3.51M shares in Tempest Therapeutics (Ticker: TPST). Most recently, Versant Venture Capital VI, L.P. Sold ― shares of Monte Rosa Therapeutics on Sep 24, 2024 for an estimated value of 7.38M.
What was Versant Venture Capital VI, L.P.’s latest transaction?
Versant Venture Capital VI, L.P. latest transaction was an Informative Sell of $7.38M.
What was Versant Venture Capital VI, L.P.'s most profitable transaction?
Versant Venture Capital VI, L.P.’s most profitable transaction was an Informative Buy of AKRO stock on June 25, 2019. The return on the trade was 39.40%.
What is Versant Venture Capital VI, L.P.'s role in Akero Therapeutics?
Versant Venture Capital VI, L.P.'s role in Akero Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.